Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis
- Correspondence to Dr Alan G Dawson, Academic Foundation Year Two, Aberdeen Royal Infirmary, Department of Cardiothoracic Surgery, Foresterhill, Aberdeen AB25 2ZN, Scotland, UK; alan.g.dawson.04{at}aberdeen.ac.uk
This randomised, multicentre, double-blind, placebo-controlled trial evaluated the efficacy and safety of four different doses of BIBF 1120, a tyrosine kinase inhibitor, in order to investigate its effect on progression of idiopathic pulmonary fibrosis (IPF).
The annual rate of decline in forced vital capacity (FVC), the primary end-point of this study, in the highest dose subgroup compared …
